Form 4: Protara Therapeutics Director Richard Levy Granted 24,000 Stock Options

Protara Therapeutics, Inc. Director Richard S. Levy was granted 24,000 stock options with an exercise price of $3.26, vesting on June 12, 2026.

Summary

• Richard S. Levy, a Director of Protara Therapeutics, Inc. (TARA), acquired 24,000 stock options.
• The stock options have an exercise price of $3.26 per share.
• The grant date for these options was June 12, 2025.
• The options are scheduled to vest in full on June 12, 2026, which marks the first anniversary of the grant date, contingent upon Mr. Levy's continuous service as a member of the Board.
• Full vesting will also occur immediately upon a Change of Control.
• The expiration date for these stock options is June 11, 2035.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a routine compensation event for a director, indicating continued commitment and alignment of interests, but does not convey significant new information about the company's operational or financial performance.

Positives

• The grant of stock options to a director aligns their financial interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service and commitment to the company's board.

Future Outlook

N/A. This Form 4 reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future operational or financial performance.

Industry Context

The grant of stock options is a common and standard practice in the biotechnology and pharmaceutical industries, particularly for directors, to align their interests with long-term shareholder value and incentivize retention. This is a typical compensation mechanism for board members.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, especially prevalent in the biotech sector, aimed at attracting and retaining qualified board members and aligning their interests with long-term shareholder value.
• The specific terms, including the exercise price and a service-based vesting schedule over one year, are consistent with common corporate governance practices for annual director equity grants.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with shareholders by incentivizing long-term stock performance and value creation.

Next Steps

• Richard S. Levy's stock options are scheduled to vest on June 12, 2026, contingent on his continuous service as a Board member.
• The options will expire on June 11, 2035, if not exercised.

Key Dates

Recommendation

Keywords

Protara Therapeutics, TARA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Richard Levy